TNG Pharmaceuticals is a Louisville, KY–based animal pharmaceutical company developing FlyVax™, a patented vaccine intended to reduce damage from horn flies in cattle. FlyVax was first developed by research scientists at Auburn University and licensed by TNG, and has shown effectiveness in initial laboratory testing. The company completed a $4.6 million Series A Preferred Stock financing to fund completion of all phases of product development and move toward commercialization. TNG says the financing will allow it to commercialize the vaccine in a timely fashion. The company originated at the University of Louisville in the Entrepreneurship MBA program and was named the 2011 Global Business Plan Champion. Management positions the product as offering significant health and economic benefits for the cattle industry.

Total raised

$5M

Funding rounds

1

Latest round

Series A

Latest activity

Feb 2014